2025 Q4 -tulosraportti
22 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Irtoamispäivä 27.3.
4,89%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 994 988
Myynti
Määrä
3 077 791
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 180 | - | - | ||
| 210 | - | - | ||
| 4 275 | - | - | ||
| 10 | - | - | ||
| 300 | - | - |
Ylin
241,7VWAP
Alin
236,45VaihtoMäärä
2 346,7 9 819 212
VWAP
Ylin
241,7Alin
236,45VaihtoMäärä
2 346,7 9 819 212
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 9 819 212 | 9 819 212 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 9 819 212 | 9 819 212 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 min sitten- ·22 min sittenFor me, there is no doubt that Novo Nordisk has a strong future in the obesity market. Not to forget the diabetes segment- The company has both the necessary products and significant production capacity, which makes it possible to manufacture large quantities at low prices. This means that Novo Nordisk can attract more customers and increase its market share, because they can fill the mass market and earn more by selling more units. A concrete example is that Novo Nordisk can utilize their advanced production facilities to manufacture obesity products like Wegovy on a large scale. This ability to produce efficiently and cheaply gives them a clear competitive advantage, as they can offer lower prices than competitors and thus make the products more accessible to more people. The year 2026 marks a transition period where the savings that have been implemented will gradually begin to take effect. It is still uncertain when a price reduction will specifically lead to sales so significant that it not only matches but also exceeds last year's profit. This is something that must be closely monitored, and the result will show itself over time. The Novo Nordisk shares I bought today for 240 kr. and 238.90 kr. respectively, I consider a better buy than those I previously acquired for 340 kr. From my point of view, there is greater value in buying when the price is lower. For me, it applies that the shares I have not yet sold yield neither gain nor loss until they are actually sold. This means that any share I own can, in principle, be for sale – either wholly or partially – if the bid is high enough to make it attractive to me.
·15 min sittenit's probably not worth buying it when they no longer have patents and other countries produce it much cheaper 
53 min sitten53 min sitten😊👍·39 min sittenFor me, there is no doubt that Novo Nordisk has a strong future in the obesity market. Not to forget the diabetes segment- The company has both the necessary products and significant production capacity, which makes it possible to manufacture large quantities at low prices. This means that Novo Nordisk can attract more customers and increase its market share because they can fill the mass market and earn more by selling more units. A concrete example is that Novo Nordisk can utilize their advanced production facilities to manufacture obesity products like Wegovy on a large scale. This ability to produce efficiently and cheaply gives them a clear competitive advantage, as they can offer lower prices than competitors and thus make the products more accessible to more people. The year 2026 marks a transition period where the savings that have been implemented will gradually begin to take effect. It is still uncertain when a price reduction will concretely lead to sales so significant that it not only matches but also exceeds last year's profit. This is something that must be closely monitored, and the result will show itself over time. The Novo Nordisk shares I bought today for 240 kr. and 238.90 kr. respectively, I consider a better purchase than those I previously acquired for 340 kr. From my point of view, there is greater value in buying when the price is lower. For me, it applies that the shares I have not yet sold yield neither gain nor loss until they are actually sold. This means that any share I own can, in principle, be for sale – either wholly or partially – if the bid is high enough to make it attractive to me.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
22 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Irtoamispäivä 27.3.
4,89%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 min sitten
- ·22 min sittenFor me, there is no doubt that Novo Nordisk has a strong future in the obesity market. Not to forget the diabetes segment- The company has both the necessary products and significant production capacity, which makes it possible to manufacture large quantities at low prices. This means that Novo Nordisk can attract more customers and increase its market share, because they can fill the mass market and earn more by selling more units. A concrete example is that Novo Nordisk can utilize their advanced production facilities to manufacture obesity products like Wegovy on a large scale. This ability to produce efficiently and cheaply gives them a clear competitive advantage, as they can offer lower prices than competitors and thus make the products more accessible to more people. The year 2026 marks a transition period where the savings that have been implemented will gradually begin to take effect. It is still uncertain when a price reduction will specifically lead to sales so significant that it not only matches but also exceeds last year's profit. This is something that must be closely monitored, and the result will show itself over time. The Novo Nordisk shares I bought today for 240 kr. and 238.90 kr. respectively, I consider a better buy than those I previously acquired for 340 kr. From my point of view, there is greater value in buying when the price is lower. For me, it applies that the shares I have not yet sold yield neither gain nor loss until they are actually sold. This means that any share I own can, in principle, be for sale – either wholly or partially – if the bid is high enough to make it attractive to me.·15 min sittenit's probably not worth buying it when they no longer have patents and other countries produce it much cheaper
- 53 min sitten53 min sitten😊👍·39 min sittenFor me, there is no doubt that Novo Nordisk has a strong future in the obesity market. Not to forget the diabetes segment- The company has both the necessary products and significant production capacity, which makes it possible to manufacture large quantities at low prices. This means that Novo Nordisk can attract more customers and increase its market share because they can fill the mass market and earn more by selling more units. A concrete example is that Novo Nordisk can utilize their advanced production facilities to manufacture obesity products like Wegovy on a large scale. This ability to produce efficiently and cheaply gives them a clear competitive advantage, as they can offer lower prices than competitors and thus make the products more accessible to more people. The year 2026 marks a transition period where the savings that have been implemented will gradually begin to take effect. It is still uncertain when a price reduction will concretely lead to sales so significant that it not only matches but also exceeds last year's profit. This is something that must be closely monitored, and the result will show itself over time. The Novo Nordisk shares I bought today for 240 kr. and 238.90 kr. respectively, I consider a better purchase than those I previously acquired for 340 kr. From my point of view, there is greater value in buying when the price is lower. For me, it applies that the shares I have not yet sold yield neither gain nor loss until they are actually sold. This means that any share I own can, in principle, be for sale – either wholly or partially – if the bid is high enough to make it attractive to me.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 994 988
Myynti
Määrä
3 077 791
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 180 | - | - | ||
| 210 | - | - | ||
| 4 275 | - | - | ||
| 10 | - | - | ||
| 300 | - | - |
Ylin
241,7VWAP
Alin
236,45VaihtoMäärä
2 346,7 9 819 212
VWAP
Ylin
241,7Alin
236,45VaihtoMäärä
2 346,7 9 819 212
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 9 819 212 | 9 819 212 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 9 819 212 | 9 819 212 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
2025 Q4 -tulosraportti
22 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 |
7,95 DKK/osake
Irtoamispäivä 27.3.
4,89%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 min sitten
- ·22 min sittenFor me, there is no doubt that Novo Nordisk has a strong future in the obesity market. Not to forget the diabetes segment- The company has both the necessary products and significant production capacity, which makes it possible to manufacture large quantities at low prices. This means that Novo Nordisk can attract more customers and increase its market share, because they can fill the mass market and earn more by selling more units. A concrete example is that Novo Nordisk can utilize their advanced production facilities to manufacture obesity products like Wegovy on a large scale. This ability to produce efficiently and cheaply gives them a clear competitive advantage, as they can offer lower prices than competitors and thus make the products more accessible to more people. The year 2026 marks a transition period where the savings that have been implemented will gradually begin to take effect. It is still uncertain when a price reduction will specifically lead to sales so significant that it not only matches but also exceeds last year's profit. This is something that must be closely monitored, and the result will show itself over time. The Novo Nordisk shares I bought today for 240 kr. and 238.90 kr. respectively, I consider a better buy than those I previously acquired for 340 kr. From my point of view, there is greater value in buying when the price is lower. For me, it applies that the shares I have not yet sold yield neither gain nor loss until they are actually sold. This means that any share I own can, in principle, be for sale – either wholly or partially – if the bid is high enough to make it attractive to me.·15 min sittenit's probably not worth buying it when they no longer have patents and other countries produce it much cheaper
- 53 min sitten53 min sitten😊👍·39 min sittenFor me, there is no doubt that Novo Nordisk has a strong future in the obesity market. Not to forget the diabetes segment- The company has both the necessary products and significant production capacity, which makes it possible to manufacture large quantities at low prices. This means that Novo Nordisk can attract more customers and increase its market share because they can fill the mass market and earn more by selling more units. A concrete example is that Novo Nordisk can utilize their advanced production facilities to manufacture obesity products like Wegovy on a large scale. This ability to produce efficiently and cheaply gives them a clear competitive advantage, as they can offer lower prices than competitors and thus make the products more accessible to more people. The year 2026 marks a transition period where the savings that have been implemented will gradually begin to take effect. It is still uncertain when a price reduction will concretely lead to sales so significant that it not only matches but also exceeds last year's profit. This is something that must be closely monitored, and the result will show itself over time. The Novo Nordisk shares I bought today for 240 kr. and 238.90 kr. respectively, I consider a better purchase than those I previously acquired for 340 kr. From my point of view, there is greater value in buying when the price is lower. For me, it applies that the shares I have not yet sold yield neither gain nor loss until they are actually sold. This means that any share I own can, in principle, be for sale – either wholly or partially – if the bid is high enough to make it attractive to me.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
2 994 988
Myynti
Määrä
3 077 791
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 180 | - | - | ||
| 210 | - | - | ||
| 4 275 | - | - | ||
| 10 | - | - | ||
| 300 | - | - |
Ylin
241,7VWAP
Alin
236,45VaihtoMäärä
2 346,7 9 819 212
VWAP
Ylin
241,7Alin
236,45VaihtoMäärä
2 346,7 9 819 212
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 9 819 212 | 9 819 212 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 9 819 212 | 9 819 212 | 0 | 0 |